Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)
复制标题
DOI：
10.1158/1078-0432.ccr-16-3155
复制
发表时间：
2017-09-15
影响因子：
11.5
通讯作者：
Zaanan, Aziz
中科院分区：
文献类型：
--
作者：
Garlan, Fanny;Laurent-Puig, Pierre;Zaanan, Aziz
目的：转移性结直肠癌（mCRC）化疗疗效的标志物对于优化治疗策略至关重要。我们评估了循环肿瘤DNA（ctDNA）的早期变化的适用性作为一个标志物的therapeutic efficacy.Experimental designation：这项前瞻性研究招募了连续的mCRC患者接受一线或二线化疗。使用基于基因突变（KRAS、BRAF、TP 53）或高甲基化（WIF 1、NPY）检测的picodroplet-digital PCR分析，在第一（C-0）、第二（C-1）和/或第三（C-2）化疗周期前采集的血浆中评估CtDNA。使用RECIST v1.1标准对CT扫描进行集中评估。多因素分析调整了年龄、性别、ECOG体能状态（PS）、转移同步性和治疗线。结果：82例mCRC患者接受一线（82.9%）或二线（17.1%）化疗。高浓度（> 10 ng/mL）与低浓度（
Purpose: Markers of chemotherapy efficacy in metastatic colorectal cancer (mCRC) are essential for optimization of treatment strategies. We evaluated the applicability of early changes in circulating tumor DNA (ctDNA) as a marker of therapeutic efficacy.Experimental Design: This prospective study enrolled consecutive patients with mCRC receiving a first-or second-line chemotherapy. CtDNA was assessed in plasma collected before the first (C-0), second (C-1) and/or third (C-2) chemotherapy cycle, using picodroplet-digital PCR assays based either on detection of gene mutation (KRAS, BRAF, TP53) or hypermethylation (WIF1, NPY). CT scans were centrally assessed using RECIST v1.1 criteria. Multivariate analyseswere adjusted on age, gender, ECOG performance status (PS), metastatic synchronicity, and treatment line.Results: Eighty-two patients with mCRC treated in first(82.9%) or second-(17.1%) line chemotherapy were included. Patients with a high (> 10 ng/mL) versus low (